CClinicalTrials.gg
CompletedNCT02707627Updated Aug 17, 2021

Laser Therapy for Pediatric Burn Scars

An observational study in Cicatrix, Hypertrophic and Burns, sponsored by The Hospital for Sick Children. Completed at 1 site in Canada. Open to participants aged 1 Year to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by The Hospital for Sick Children · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
1 Year to 18 Years
Sex
All
01

Study summary

A new era of outcomes for pediatric burn patients has begun as burn care continues to improve. Unfortunately, complete restoration of burn-injured skin may be limited by the development of hypertrophic scarring. Treatment with laser therapy is one of the newest forms of scar therapy available. Although laser therapy has only been adopted by burn clinicians within the last several years, early evidence suggests that it may offer significant benefits. Thus the aim of this study is to investigate the effectiveness of using laser therapy to treat hypertrophic burn scars in pediatric patients by using a comprehensive set of subjective and objective scar assessment tools.

02

Conditions studied

  • Cicatrix, Hypertrophic
  • Burns

Keywords

  • Pediatric
  • Laser
  • Burn
  • Scar
  • Photothermolysis
03

In context

Cicatrix

307 studies on the registry are indexed under Cicatrix; 50 are open to participants now.

This study's enrollment of 20 is below the median of 38 across 34 observational studies indexed under Cicatrix.

Browse Cicatrix studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 568 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Eligible participants will be pediatric patients with hypertrophic scars requiring treatment.

Inclusion criteria

  1. Age 1-18 years at presentation
  2. Patients with a hypertrophic burn scar that has been clinically diagnosed by a burn care specialist
  3. Hypertrophic burn scar resulting from any etiology
  4. Hypertrophic burn scar is ≥ 2 months post healing
  5. Ability to complete English- language questionnaires

Exclusion criteria

Exclusion Criteria:

  1. Patients with concomitant skin disease (i.e. chronic skin conditions, herpes infection)
  2. Patients with a history of keloid scarring
  3. Patients who cannot tolerate the intravenous (IV) sedation used to perform laser therapy procedures
  4. Patients who have had previous laser therapy procedures
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • Laser Therapy

    Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.

    Device: Laser Therapy

Interventions

  • DeviceLaser Therapy

    Laser therapy is a technology that can be used to treat hypertrophic burn scars.

06

What researchers measure

Primary outcomes

  1. Vancouver Scar Scale Score

    The Vancouver Scar Scale is composed of four subscales which include pigmentation (range: 0 - 3), vascularity (range: 0 - 3), pliability (range: 0 - 5), and height (range: 0 - 3). Total Vancouver Scar Scale score refers to the score obtained by summing the values from each subscale (range: 0 - 14) with higher scores indicating a worse scar.

    Time frame: Baseline (month 0) to month 12

Secondary outcomes

  1. Patient and Observer Scar Assessment Scale Score

    The Patient and Observer Scar Assessment Scale consists of two independent scales: 1) the patient scale (patient-reported), and 2) the observer scale (clinician-reported). Both the patient scale as well as the observer scale include a set of individual subscales that assess scar severity (range: 1 - 10) with higher scores indicating a worse scar.

    Time frame: Baseline (month 0) to month 12

  2. Scar thickness

    Scar thickness measurements will be taken at five study visits over the course of one year and will be measured using ultrasonography.

    Time frame: Baseline(month 0) to month 12

  3. Scar stiffness measured by the DermaLab Combo® skin analysis device

    Scar stiffness measurements will be taken at five study visits over the course of one year and will be measured using the DermaLab Combo® skin analysis device (Cortex Technologies, Hadsund, DK).

    Time frame: Baseline(month 0) to month 12

  4. Scar stiffness measured by ultrasound elastographgy

    Scar stiffness measurements will be taken at five study visits over the course of one year and will be measured using ultrasound elastography.

    Time frame: Baseline(month 0) to month 12

  5. Scar colour

    Scar colour measurements will be taken at five study visits over the course of one year and will be measured using the DermaLab Combo® skin analysis device (Cortex Technologies, Hadsund, DK)

    Time frame: Baseline(month 0) to month 12

07

Study locations

1 site
  • Hospital for Sick Children
    Toronto, Ontario M5G1X8, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02707627
Lead sponsor
The Hospital for Sick Children
Responsible party
Joel Fish (Medical Director, Burn Program, The Hospital for Sick Children) — Principal investigator
First posted
Mar 14, 2016
Start date
Oct 2016
Primary completion
May 2020
Completion
Jan 2021
Last update
Aug 17, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion